Tislelizumab Combined With Anlotinib and Nab-paclitaxel in III Resectable Non-small Cell Lung Cancer(TitAN) : A Prospective, Single-Arm, Phase II Study
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Clinical Trials Related to NSCLC
Related studies linked through entity extraction aliases.
A Phase II Randomized Trial of Neoadjuvant Ivonescimab or Penpulimab Plus Chemotherapy in Resectable NSCLC
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Tislelizumab Combined With sCRT in Stage IIIB/C-IV Non-Squamous Non-Small Cell Lung Cancer：A Prospective, Single-Arm, Phase II Study
- Status
- RECRUITING
- Phase
- PHASE2
A Prospective Phase II Clinical Study of Immunotherapy Combined With Chemotherapy for Stage III Unresectable Non-small Cell Lung Cancer
- Status
- RECRUITING
- Phase
- PHASE2
Adebrelimab + Chemotherapy as Neoadjuvant Therapy for Resectable NSCLC
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
A Study to Assess the Efficacy and Safety of Firmonertinib Versus Placebo for Adjuvant Treatment in Participants With Stage IB - IIIB NSCLC With Uncommon Epidermal Growth Factor Receptor (EGFR) Mutations, Following Complete Surgical Resection With or Without Adjuvant Chemotherapy（FIRMOST）
- Status
- RECRUITING
- Phase
- PHASE3
A Clinical Trial of Furmonertinib Combined With Anlotinib as First-line Treatment for Advanced NSCLC With EGFR-sensitive Mutations and Brain Metastasis
- Status
- RECRUITING
- Phase
- PHASE2
JS207 Combined With Chemotherapy in Subjects With Stage II-III NSCLC
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
JS111 in Patients With Advanced NSCLC Harboring EGFR Mutations
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Adaptive Therapy for Resected Stage ⅠA2-Ⅱ NSCLC Patients With Undetectable MRD
- Status
- RECRUITING
- Phase
- NA
Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
BBO-11818 in Adult Subjects With KRAS Mutant Cancer
- Status
- RECRUITING
- Phase
- PHASE1
Study on c-Met Targeted PET/CT Imaging in NSCLC
- Status
- RECRUITING
- Phase
- NA
Explore the Mechanisms Underlying Disease Resistance and Potential Primary Resistance Mechanism of Induction Therapy Lorlatinib in Resectable Non-small Cell Lung Cancer (NSCLC) Harboring ALK Positive Mutation Revealed by Single-cell RNA Sequencing and Spatial Transcriptomics
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE4
A Long-Term Follow-Up Study of Participants Treated With A2 Biotherapeutics (A2 Bio) Gene Therapy (GT) Products
- Status
- ENROLLING_BY_INVITATION
- Phase
- N/A
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
- Status
- RECRUITING
- Phase
- PHASE3
Thoracic Radiotherapy and Inhibition of PD-1 and LAG-3 for Locally Advanced Non-Small Cell Lung Cancer
- Status
- RECRUITING
- Phase
- PHASE2
Perioperative Treatment of Sunvozertinib in Stage II-IIIB NSCLC
- Status
- RECRUITING
- Phase
- PHASE2
A Phase II Clinical Study of SHR-1826 for Injection in Patients With NSCLC
- Status
- RECRUITING
- Phase
- PHASE2
Study Investigating Anti-drug Antibodies in NSCLC Patients Exposed to Checkpoint Inhibitors (IMB)
- Status
- RECRUITING
- Phase
- N/A